

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-12. (Canceled)

13. (Currently Amended) A monoclonal antibody ~~An isolated binding agent~~ that competes with a monoclonal antibody MAb 763-15-5 (ATCC PTA-1079) for specific binding to the human cytochrome p450 2C9 allelic variants 2C9*1, 2C9*2, and 2C9*3, and that specifically inhibits 2C9*1, 2C9*2, and 2C9*3 ~~[[2C-]]~~ catalyzed metabolism of phenanthrene by at least 50%, wherein binding between the monoclonal antibody and the human cytochrome p450 2C9 allelic variants 2C9*1, 2C9*2, and 2C9*3 is detectable by an enzyme-linked immunosorbent assay.

14. (Currently Amended) The monoclonal antibody ~~binding agent~~ of claim 13 that lacks specific binding to each of human cytochromes P450 1A1, 1A2, 2A6, 2B6, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, and 3A5.

15. (Currently Amended) The monoclonal antibody ~~binding agent~~ of claim 13 that specifically inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic variant 2C9*2 by at least 90%.

16. (Currently Amended) The monoclonal antibody ~~binding agent~~ of claim 13; that is MAb 292-2-3 (ATCC HB-12645) or a binding fragment thereof that binds to 2C9*2, wherein the specific binding is to human cytochrome p450 2C9 allelic variant 2C9*2.

17. (Canceled)

18. (Currently Amended) The monoclonal antibody of claim 13 ~~[[17]]~~ that is a Fab fragment.
19. (Currently Amended) The monoclonal antibody of claim 13 ~~[[17]]~~ that is a mouse antibody.
20. (Currently Amended) A cell line producing the monoclonal antibody of claim 13 ~~[[17]]~~.
21. (Original) The cell line of claim 20 that is a eucaryotic cell line.
22. (Currently Amended) The cell line of claim 20 ~~[[21]]~~ that is a procaryotic cell line.
23. (Currently Amended) The monoclonal antibody of claim 13 ~~[[17]]~~ comprising a light chain variable domain having at least 80% sequence identity with the light chain variable domain of a monoclonal antibody MAb 763-15-5 (ATCC PTA-1079) and a heavy chain variable domain having at least 80% sequence identity with the heavy chain variable domain of the monoclonal antibody MAb 763-15-5.
24. (Currently Amended) The monoclonal antibody of claim 13 ~~[[17]]~~, wherein the light chain variable domain comprises the three CDR regions from the light chain of a monoclonal antibody MAb 763-15-5 (ATCC PTA-1079), and the heavy chain variable domain comprises the three CDR regions from the heavy chain of the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).

25. (Currently Amended) The monoclonal antibody binding agent of claim 13 that specifically inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 allelic variants 2C9*1 and 2C9*3 by at least 70%.

26. (Currently Amended) The monoclonal antibody binding agent of claim 13 that specifically inhibits the phenanthrene metabolism enzyme activity of human cytochrome P450 2C18 by 30%.

27-73. (Canceled)

74. (New) The monoclonal antibody of claim 13, wherein the monoclonal antibody comprises the monoclonal antibody MAb 763-15-5 (ATCC PTA-1079).